Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO1993018648) CELLULES PRECURSEURS NEUTROPHILES HUMAINES OBTENUES $i(IN VITRO)
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED IS:

1. A composition of human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% myeloblasts and promyelocytes and less than about 5% colony forming units.

2. The composition of claim 1, wherein said neutrophil precursor cells have the capacity to
proliferate and differentiate into segmented neutrophils.

3. The composition of claim 2 , which is
substantially free of erythroid lineage-committed cells, including BFU-E.

4. The composition of claim 2 , which additionally comprises one or more cell types selected from the group consisting of myelocytes, metamyelocytes, banded
neutrophils, and segmented neutrophils.

5. The composition of claim 4, wherein said additional cell types are derived from said neutrophil precursor cells jLn vitro.

6. The composition of claim 1, wherein said neutrophil precursor cells are derived from neutrophil progenitor cells obtained from a source selected from the group consisting of peripheral blood, bone marrow, and cord blood.

7. A composition of human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CDllb- neutrophil precursor cells and less than about 5% colony forming units.

8. The composition of claim 7, wherein said
CD15+CDllb- cells are comprised of myeloblasts and promyelocytes.

9. The composition of claim 8, wherein said
CD15+CDllb- cells are at least about 60% myeloblasts and promyelocytes.

10. The composition of claim 8, wherein said
CD15+CDllb- cells have the capacity to proliferate and differentiate into segmented neutrophils.

11. The composition of claim 10, which is
substantially free of erythroid lineage-committed cells, including BFU-E.

12. The composition of claim 10, which additionally comprises one or more cell types selected from the group consisting of myelocytes, metamyelocytes, banded
neutrophils, and segmented neutrophils.

13. The composition of claim 12, wherein said additional cell types are derived from said CD15+CDllb-cells in vitro.

14. The composition of claim 7, wherein said
CD15+CDllb- cells are derived from neutrophil progenitor cells obtained from a source selected from the group consisting of peripheral blood, bone marrow, and cord blood.

15. A method of treating a human patient having a reduced population of neutrophils, which method comprises administering to said patient a composition of human neutrophil precursor cells, wherein the cellular
component is comprised of at least about 16% myeloblasts and promyelocytes and less than about 5% colony forming units.

16. The method of claim 15, wherein said human patient is suffering from a neutropenia selected from the group consisting of neutropenia associated with high dose chemotherapy (HDC) , neutropenia associated with
conventional oncology therapy, drug-induced neutropenia, disease-induced neutropenia, genetic neutropenia,
toxin-induced neutropenia, and radiation-induced
neutropenia.

17. The method of claim 15, wherein said
composition is administered intravenously.

18. The method of claim 15, wherein said neutrophil precursor cells have the capacity to proliferate and differentiate into segmented neutrophils.

19. The method of claim 18, wherein said
composition is substantially free of erythroid
lineage-committed cells, including BFU-E.

20. The method of claim 18, wherein said
composition additionally comprises one or more cell types selected from the group consisting of myelocytes,
metamyelocytes, banded neutrophils, and segmented
neutrophils.

21. The method of claim 20, wherein said additional cell types are derived from said neutrophil precursor cells in vitro.

22. The method of claim 15, wherein said neutrophil precursor cells are derived from neutrophil progenitor cells obtained from a source selected from the group consisting of peripheral blood, bone marrow, and cord blood.

23. The method of claim 15, which method
additionally comprises the co-administration of stem cells and other progenitor cells.

24. A method of treating a human patient having a reduced population of neutrophils, which method comprises administering to said patient a composition of human neutrophil precursor cells, wherein the cellular
component is comprised of at least about 16% CD15+CDllb-neutrophil precursor cells and less than about 5% colony forming units.

25. The method of claim 24, wherein said human patient is suffering from a neutropenia selected from the group consisting of neutropenia associated with high dose chemotherapy (HDC) , neutropenia associated with
conventional oncology therapy, drug-induced neutropenia, disease-induced neutropenia, genetic neutropenia, toxin-induced neutropenia, and radiation-induced neutropenia.

26. The method of claim 24, wherein said
composition is administered intravenously.

27. The method of claim 24, wherein said
CD15+CDllb- cells are comprised of promyelocytes and myeloblasts.

28. The method of claim 27, wherein said
CD15+CDllb- cells are at least about 60% myeloblasts and promyelocytes.

29. The method of claim 27, wherein said
CD15+CDllb- cells have the capacity to proliferate and differentiate into segmented neutrophils.

30. The method of claim 29, wherein said
composition is substantially free of erythroid lineage-committed cells, including BFU-E.

31. The method of claim 29, wherein said
composition additionally comprises one or more cell types selected from the group consisting of myelocytes,
metamyelocytes, banded neutrophils, and segmented
neutrophils.

32. The method of claim 31, wherein said additional cell types are derived from said CD15+CDllb- cells in vitro.

33. The method of claim 24, wherein said
CD15+CDllb- cells are derived from neutrophil progenitor cells obtained from a source selected from the group consisting of peripheral blood, bone marrow, and cord blood.

34. The method of claim 24, which method
additionally comprises the co-administration of stem cells and other progenitor cells.

35. A method of human gene therapy, which method comprises:
(a) the introduction of DNA into neutrophil
progenitor cells, wherein said DNA is selected from the group consisting of a wild-type human gene and a gene for resistance to a drug, (b) the in vitro proliferation and
differentiation of said neutrophil progenitor
cells into neutrophil precursor cells, and
(c) the administration of a composition
comprising said neutrophil precursor cells to a patient.

36. The method of claim 35, wherein said
composition is administered intravenously.

37. The method of claim 35, wherein said gene for resistance to a drug is a gene for resistance to a chemotherapeutic drug and said patient will be exposed to said chemotherapeutic drug.

38. A method of human gene therapy, which method comprises:
(a) the introduction of DNA into neutrophil
precursor cells, wherein said DNA is selected
from the group consisting of a wild-type human gene and a gene for resistance to a drug, and
(b) the administration of a composition
comprising said neutrophil precursor cells to a human patient.

39. The method of claim 38, wherein said
composition is administered intravenously.

40. The method of claim 38, wherein said gene for resistance to a drug is a gene for resistance to a chemotherapeutic drug and said patient will be exposed to said chemotherapeutic drug.